NCT04394624 - Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

March 6, 2023

Study Completion Date

October 24, 2024

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG

SAR408701

Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion

DRUG

ramucirumab

Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion

DRUG

pembrolizumab

Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion

Trial Locations (13)

Investigational Site Number : 1000001, Plovdiv

Investigational Site Number : 2030002, Prague

Roswell Park Cancer Institute Site Number : 8400003, Buffalo

Investigational Site Number : 7240004, Madrid

Investigational Site Number : 7240005, Madrid

Henry Ford Hospital Site Number : 8400005, Detroit

Investigational Site Number : 7240003, Zaragoza

McClinton Cancer Center Site Number : 8400002, Waco

Investigational Site Number : 2030001, Ostrava - Vitkovice

Investigational Site Number : 6200001, Porto

Investigational Site Number : 4100001, Seoul

Investigational Site Number : 4100002, Seoul

Investigational Site Number : 7240001, Barcelona / Sabadell